论文部分内容阅读
纽约长岛犹太医院的Dr.Robert A.Silverman及其同事报道:硫酸镁静脉注射有助于严重急性哮喘患者的标准治疗,并指出以前此类研究的结果不一。他们观察到这种治疗方法不适用于轻度到中度的哮喘患者。 研究人员对240名被送至急诊室需要进行抗哮喘治疗的患者进行了研究。刚到急诊室时,他们的肺功能(FEV1)只有30％或更弱,对所有患者均规律间歇的进行舒喘灵喷雾治疗,并静脉注射甲基泼尼松龙(methylprednisolone)。此外,在这些患者送至急诊室半小时后,还接受了2g硫酸镁静脉注射或安慰剂注射。
Dr. Robert A. Silverman of Long Island Jewish Hospital in New York City and colleagues reported that intravenous magnesium sulfate helped standard-of-care treatment in patients with severe acute asthma and noted differences in the results of previous studies. They observed that this treatment is not suitable for mild to moderate asthma patients. The researchers studied 240 patients who were sent to the emergency room for anti-asthma treatment. At the emergency room, their lung function (FEV1) was only 30% or weaker. All patients were regularly treated with salbutamol nebulization and methylprednisolone intravenously. In addition, these patients received an intravenous injection of 2 g magnesium sulfate or placebo after a half hour’s delivery to the emergency department.